> India's Sun Pharmaceutical Industries has tendered to buy all of U.S.-based eyecare firm InSite Vision to build on its basket of specialty products in a deal valued at INR3 billion ($48 million), the company said in a notice to the Mumbai stock exchange. The bid trumped a notice in August that saw InSite Vision agree to a deal with Canadian drugmaker QLT at a value band of $0.25 and $0.30 per share; the Sun offer is $0.35 per share. InSite notified stock exchanges on Sept. 4 that it had received an unsolicited offer that constituted a "Company Superior Proposal," the Economic Times newspaper had reported. However, an investment banking source said Sun may have to pay a termination fee of $2.7 million to secure the deal. The Economic Times, citing reports, said InSite expects New Drug Approvals from the U.S. FDA for its two drugs, BromSite and DexaSite, in the medium term. Release (PDF)
> Zhejiang Hisun Pharma, a joint venture with Pfizer ($PFE), has received a U.S. FDA warning letter over insufficient data for 29 of its active pharmaceutical ingredients, with 15 halted for import into the United States. The action may cost the company sales of RMB72.4 million ($11.36 million) in the fourth quarter of 2015. Release (Chinese language)
> Singapore's MerLion Pharmaceuticals will release Phase II clinical trial data on its candidate finafloxacin in patients with urinary tract infections and pyelonephritis at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy and International Society of Chemotherapy International Congress of Chemotherapy and Infection this week in San Diego. Release
> More progress is needed to eliminate the transmission of HIV and syphilis, as thousands of mothers and children have yet to feel the benefits of programs to help, the 10th Asia-Pacific United Nations Parent-to-Child Transmission of HIV and Syphilis Task Force meeting in Beijing heard this week, according to China Daily. Report
> Cambodia organized its first international exhibition on the pharmaceutical and medical industry this week, Xinhua said, with interest growing in the development of the sector. Report
> Hong Kong has seen a women's health expert question whether birth control drugs that contain drospirenone should only be available by prescription, citing an increased incidence of dangerous blood clots noted in a U.K. study, the South China Morning Post said. But the government said it had no recorded incidences of blood clots directly related to the pills in Hong Kong and that additional warnings had already been affixed to packaging. Report
> Researchers at Russia's Belozersky Research Institute at Moscow State University and the Wenner-Gren Institute at Stockholm University are investigating a potential new obesity treatment called C12-TPP that produces rapid weight loss, with hopes for clinical trials in two years. Report